These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 11278833)
1. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. Liu S; Bugge TH; Leppla SH J Biol Chem; 2001 May; 276(21):17976-84. PubMed ID: 11278833 [TBL] [Abstract][Full Text] [Related]
2. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin. Liu S; Bugge TH; Frankel AE; Leppla SH Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974 [TBL] [Abstract][Full Text] [Related]
3. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100 [TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700 [TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Rønø B; Rømer J; Liu S; Bugge TH; Leppla SH; Kristjansen PE Mol Cancer Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16432166 [TBL] [Abstract][Full Text] [Related]
6. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Liu S; Netzel-Arnett S; Birkedal-Hansen H; Leppla SH Cancer Res; 2000 Nov; 60(21):6061-7. PubMed ID: 11085528 [TBL] [Abstract][Full Text] [Related]
7. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Petersen LC Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959 [TBL] [Abstract][Full Text] [Related]
8. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. Ellis V J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951 [TBL] [Abstract][Full Text] [Related]
9. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739 [TBL] [Abstract][Full Text] [Related]
10. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305 [TBL] [Abstract][Full Text] [Related]
11. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin). Wang J; Mazar A; Quan N; Schneider A; Henkin J Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034 [TBL] [Abstract][Full Text] [Related]
12. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830 [TBL] [Abstract][Full Text] [Related]
13. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627 [TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284 [TBL] [Abstract][Full Text] [Related]
15. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174 [TBL] [Abstract][Full Text] [Related]
16. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase. Vines DJ; Lee SW; Dichek DA; Ellis V J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879 [TBL] [Abstract][Full Text] [Related]